Real-World Treatment of Patients With Relapsed/Refractory Myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Pharmacology

Background:

• Multiple myeloma treatment has advanced with novel agents and combinations, improving outcomes in clinical trials.
• The real-world effectiveness and safety of these novel agents in relapsed/refractory multiple myeloma require further investigation.

Purpose of the Study:

• To evaluate the impact of novel agents and their combinations in real-world clinical practice for multiple myeloma.
• To compare real-world data with pivotal clinical trial findings regarding efficacy and safety.

Main Methods:

• Analysis of real-world data on proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies in relapsed/refractory multiple myeloma.
• Consideration of patient selection, comorbidities, disease characteristics, and treatment setting as potential variables.

Main Results:

• Real-world data confirm the efficacy of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
• Magnitude of benefit and safety profiles may differ between real-world studies and clinical trials due to patient heterogeneity and other factors.
• Medical center expertise and drug access influence treatment outcomes.

Conclusions:

• Clinical trial and real-world data are complementary for understanding treatment effectiveness in multiple myeloma.
• Real-world observations can inform the design of future clinical trials, including retreatment studies.
• Integrating both data sources is crucial for optimizing clinical trial design and improving patient care.